Navigation Links
The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System

Key words: somatostatin • receptor binding assay LEADseeker SPA Imaging Beads


Somatostatin (SS) is a neurotransmitter/hormone with a wide range of biological actions (1–3) and a reduction in cortical SS levels has been reported in Alzheimer’s and Parkinson’s diseases. The SS analog, octreotide (SMS 201–995), is used clinically in the treatment of certain tumors, carcinoid syndrome, and glucagonoma. Somatostatin inhibits cell proliferation and growth hormone secretion through interaction with SS receptors (4). Five SS receptors have been cloned and many studies have investigated the tissue distribution, expression, binding affinity to SS, and down-stream signal transduction pathways of these five receptors (5, 6). It has also been shown that SS receptors are G protein coupled. All five SS receptors have similar binding affinities to their natural ligand SS; however, they bind SS analogs, such as octreotide, at different affinities.

This application note describes a 384-well somatostatin sst4 receptor-binding assay which has been developed on the LEADseeker™ Multimodality Imaging System.


Materials
Reagents and instrumentation
LEADseeker Multimodality Imaging System 18-1140-71

Polyethyleneimine (PEI) PS SPA Imaging Beads RPNQ0098

(3-[125I] iodotyrosyl11) Somatostatin-14(tyr11), IM161-50UCI
1.85 MBq, 50 µCi


Other material required
Human recombinant somatostatin sst4 receptor membrane preparation (Euroscreen, ES-524-M)

Somatostatin-28 (Sigma, S-6135)

Octreotide (Sigma, O-1014)

384-well white flat-bottom polystyrene, not-treated microplates, non-sterile (Corning, 3705)

Assay buffer: 25-mM HEPES, pH 7.4, 5-mM MgCl2, 1-mM CaCl2, 100-µg/ml bacitracin, and 0.2% (w/v) protease-free BSA.

GraphPad Prism™ software (GraphPad Software).


Protocol
Human recombinant somatostatin sst4 receptor membrane preparation produced in CHO-K1 cells was used in conjunction with (3-[125I] iodotyrosyl11) Somatostatin-14(tyr11) and PEI PS SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 2-µM somatostatin-28. The standard assay format was as follows.

1. Reagents were added in the following order: assay buffer or buffer containing 2% (v/v) DMSO solution, unlabeled ligand (NSB wells), labeled ligand, and premixed bead and membrane. Total assay volume was 40 µl.

2. Diluted membrane and bead were precoupled at room temperature immediately prior to assay addition.

3. Wells contained 10 µl (~ 55 000 dpm) of 1.25-nM (3-[125I] iodotyrosyl11) Somatostatin-14(tyr11) (final concentration 0.313 nM), 62.5 µg of SPA Imaging Bead, 0.313 µg of receptor preparation added together in a 20-µl volume, and 10 µl of assay buffer in the absence of competing ligand. For competition assays, 10 µl of competing ligand prepared in assay buffer containing 2% (v/v) DMSO was added with (3-[125I] iodotyrosyl11) Somatostatin-14(tyr11) (10 µl, as above), precoupled bead, and receptor (20 µl), also giving a total assay volume of 40 µl.

4. NSB wells contained 10 µl of 1.25-nM (3-[125I] iodotyrosyl11) Somatostatin-14(tyr11) (final concentration 0.313 nM), 62.5 µg of SPA Imaging Bead, 0.313 µg of receptor preparation added together in a 20-µl volume, and 10 µl of 8-µM unlabeled somatostatin-28 (final concentration 2 µM).

5. For DMSO tolerance studies, DMSO was diluted in assay buffer to give final concentrations per well as shown in the results.

6. Plates were sealed and incubated overnight at room temperature (20–25 ºC).

7. Following incubation, plates were imaged on the LEADseeker Multimodality Imaging System for 5 min with quasi-coincident averaging and 3 x 3 binning.

8. For background estimation, bead-only wells (62.5 µg of bead/well, 20 µl), plus assay buffer (20 µl) were included in all experiments. Typically backgrounds exhibited from bead-only wells were less than 10 integrated optical density (IOD) units, and were routinely subtracted from total and NSB values during data analyses.


Results
Kd determination
Saturation binding was carried out with dilutions of (3-[125I] iodotyrosyl11) Somatostatin-14(tyr11) to give a range of concentrations from 0.0 0347–3.00 nM in the assay wells. The saturation curve (Fig 1) was fitted using non-linear regression with the data analysis package GraphPad Prism v4.0. A Kd value of 0.379 nM (95% confidence intervals 0.298–0.460 nM) was estimated directly from the curve.

DMSO tolerance
Dilutions of DMSO were prepared in assay buffer to give a range of concentrations from 0.125 to 32% (v/v) in the assay wells. From the results shown in Figure 2, it can be seen that the assay was tolerant of DMSO up to a final concentration of 2% (v/v).

IC50 determination
Competition binding of 0.313 nM (~ 55 000 dpm) (3-[125I] iodotyrosyl11) Somatostatin-14(tyr11) with unlabeled somatostatin-28 and octreotide were assessed and the IC50 values calculated (Fig 3). For the competition assays, the unlabeled ligands were prepared in assay buffer containing 2% (v/v) DMSO over the following ranges: somatostatin-28 (0.119 pM–1 µM) and octreotide (0.119 pM–8 µM).

For somatostatin-28, the IC50 value was 2.58 nM (95% confidence interval range 2.02 to 3.30 nM) and the Ki value was 1.42 nM (95% confidence interval range 1.11 to 1.81 nM). For octreotide, the IC50 value was 2.63 µM (95% confidence interval range 1.01 to 6.89 µM) and the Ki value was 1.44 µM (95% confidence interval range 0.55 to 3.77 µM).

Time course
A time course experiment was carried out using reagent concentrations as described in the protocol. Measurements were made over an assay incubation time of 20.5 h. The assay reached equilibrium after 6-h incubation at room temperature, and the signal was stable for at least another 14 h (Fig 4).

Z’ analysis
A Z’ analysis was carried out using 48 replicate values for total and NSB wells. Z’ was 0.85 (Fig 5), which confirmed the robustness of the assay (7).


Conclusions
The somatostatin sst4 receptor-binding assay has been successfully miniaturized to a 384-well format on LEADseeker Multimodality Imaging System. The assay is suitable for high-throughput screening and is tolerant up to 2% DMSO (v/v). The assay is robust, exhibiting a Z’ value of 0.85, and has a stable signal of at least 14 h.


References
1. Bell, G.I. and Reisine, T.R., Trends Neurosci. 16, 34–38 (1993).

2. Epelbaum, J., Prog. Neurobiol. 27, 63–100 (1986).

3. Rens-Domiano, S and Reisine, T.R. J., Neurochem. 58, 1987–1996 (1992).

4. Li, M., et al. World J. Surg., 29, 293–296 (2005).

5. Benali, N., et al. Digestion 62, 27–32 (2000).

6. Fisher, W.E., et al. J. Natl. Cancer Inst. 90, 322–324 (1998).

7. Zhang, J., et al. J. Biomol. Screening 4, 67–73 (1999).



back to top
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
3. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
4. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
5. The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System
6. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
7. LiquiChip Kits for bead-based cytokine and kinase assays
8. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
9. High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system
10. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
11. Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B
Post Your Comments:
(Date:8/21/2014)... (PRWEB) August 21, 2014 DNA vaccine ... progress in its development of JRC-LAMP-vax, an innovative and ... pollen. Phase IC studies began this month in Hawaii, ... hay fever. , The Japanese red cedar releases pollen ... in Japan. Mountain Cedar pollen wreaks similar havoc in ...
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
(Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... -- PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that its financial ... released on Thursday, May 14, 2009.PharmAthene management will be ... 2009 financial results. The call is scheduled to ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced its financial ... a net loss for the first quarter of 2009 of $10.9 ... Company,s expectations. This compares to a net loss for the ... Research and development expenses in the first quarter of 2009 ...
... DNDN ) today announced that management will present at the ... Merrill Lynch 2009 Health Care Conference, The New York ... 9:20 a.m. ET, Deutsche Bank Securities 34th Annual Healthcare ... 2009, 4:35 p.m. ET, Leerink Swann ...
Cached Biology Technology:Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 5
(Date:8/21/2014)... LAWRENCE A study recently published in the journal ... Kansas shows a new role for the protein adenomatous ... second-leading cause of cancer-related deaths in the U.S. , ... of Molecular Biosciences and co-leader of the Cancer Biology ... better part of her career trying to understand the ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
(Date:8/21/2014)... developed a novel and versatile modeling strategy to simulate ... materials as well as for studying polyelectrolytes, including DNA ... model much larger and more complex polyelectrolyte systems, and ... lead author of a paper on the work and ... Science and Engineering. "This is a big step forward ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... liver disease, extent of tissue damage depends on the balance ... new liver cells. In a significant minority of people who ... form scars. This can progress to chronic liver disease and ... unable to clean blood or produce vital hormones and clotting ...
... a type of cell that can be activated by tissues ... attack our own molecules, cells and organs, UCSF researchers have ... new strategies for fighting a range of autoimmune diseases ... and cells within us as well as for preventing ...
... CHICAGO A low-calorie diet eliminates insulin dependence ... with type 2 diabetes, according to a study presented ... of North America (RSNA). "Lifestyle interventions may have ... patients," said the study,s lead author, Sebastiaan Hammer, M.D., ...
Cached Biology News:The immune system has protective memory cells, researchers discover 2The immune system has protective memory cells, researchers discover 3Restricted calorie diet improves heart function in obese patients with diabetes 2
... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
... (A) and 36kDa (C) subunits Formulation: ... 500mM NaCl, 60mM 2-mercaptoethanol, 1mM MgCl2, ... and 0.1mg/ml serum albumin Properites: For ... Purification: DEAE chromatography, aminohexyl-agarose and gel ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Biology Products: